Fri, Feb 27, 2015, 8:25 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Inergy, L.P. Message Board

wilderguide 183 posts  |  Last Activity: 22 hours ago Member since: Jan 13, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    MEK Inhibitor-Induced Dusky Erythema

    by franca_ole Nov 29, 2014 7:13 AM
    wilderguide wilderguide Nov 29, 2014 12:49 PM Flag

    $$$$
    If you actually believe it takes courage to tolerate the likes of yourself...
    ...you truly are one very misguided, misbegotten twit...

  • Reply to

    hi all

    by giobui1422 Nov 29, 2014 1:46 PM
    wilderguide wilderguide Nov 29, 2014 2:30 PM Flag

    $$$$
    Offsite, you crack me up...how many aliases do you work?
    "giobui1422
    1 post | Last Activity: 37 minutes ago
    Member since: Nov 29, 2014"

  • wilderguide by wilderguide Nov 30, 2014 5:05 PM Flag

    $$$$
    ...seems to be getting a bit edgy, and I clearly see it as a "tell".... He's become a nervous Nellie.
    Every EXEL poster posting positivity - day or night...rain or shine...up-market or down...
    Has been parlayed by Seymourjiznu with derision...zero shareholder equity...
    Blah,blah, blah...
    Baghdad Bob...carnival barkers....longs aren't as cool as me...
    Blah, blah, blah...
    Get ready to grab yer ankles and smile, dooshwaddle...
    Yonder comes Big Papa...

  • Reply to

    No posts from Wilderguide for awhile

    by hans.anderson18 Dec 11, 2014 9:32 PM
    wilderguide wilderguide Dec 12, 2014 5:35 PM Flag

    $$$$
    Dontchya'll go gettin' all drama queen, sunshine meth-head gummy-bear goo-goo dolls and tweaker lollipops crazy on me...It's simply "holidays going on" and ol' franca_ole is posting updates regularly - Good job - by the way...
    Lotsa good research going on for those willing to look, and the future of cMET inhibition is continually being highlighted by new trials being fronted by OPM. My optimism for Cabo remains, I feel cobimetinib value exploration is in its infancy, and I wish the best for all in 2015. Have a Happy...

  • Reply to

    No posts from Wilderguide for awhile

    by hans.anderson18 Dec 11, 2014 9:32 PM
    wilderguide wilderguide Dec 13, 2014 11:19 PM Flag

    $$$$
    ..."you rescuing horses again..??"
    My wife still networks to re-home equines at risk of slaughter. I've discouraged her from personally keeping anymore for a spell. We've currently got 10, 6 of which are rideable. It leaves us a lot of chores, and I'm a bit challenged when the days are winter-shortened. This past year, my wife and I have rehabbed and re homed 8 others, and I'm more comfortable time-wise with the smaller herd. Everybody gets more attention. Feed bills are easier to manage. We'll see how long that lasts... Merry Christmas to you, Joe...

  • wilderguide wilderguide Dec 16, 2014 6:44 PM Flag

    $$$$
    Franca, see the document:
    "Guidance for Industry: Expedited Programs for Serious Conditions – Drugs and Biologics" published as an update May 2014... There are special considerations that apply to accelerated approval, and data suggests BRAFi monotherapy w/ Vemurafenib has enabled a less effective follow-up when followed by combo V&C (the combination is actually less effective in the wake of prior BRAFi treatment.) I think there may be a shot at early approval with a rolling review, and Roche has experience with this type of filing. I expect the NCCN will soon address this issue, and an ADCOM would likely result to work through the details of the complicated rolling review process. Keep up the good work...

  • wilderguide wilderguide Dec 16, 2014 7:50 PM Flag

    $$$$
    I knew you couldn't possibly resist commentary such as this...
    Merry Christmas, drizzle britches...

  • wilderguide by wilderguide Dec 19, 2014 6:03 AM Flag

    $$$$
    Having spent some time looking for partnering conditions, milestones, royalties, etc... I found this comment in today's Boston Globe:
    "Shares of Agenus Inc. jumped on news that a test run by partner GlaxoSmithKline for a vaccine that relies on a molecule developed at the Lexington firm has ended in success, not only for potential shingles sufferers but for those with other diseases. Glaxo said a trial of its experimental drug greatly reduced chances of getting the common, virus-borne disease among patients enrolled in the trial. If the drug is approved, Agenus would get an undisclosed percentage of royalties. Agenus’s molecule makes the vaccine more powerful."
    Anyone know if a milestone payment is attached to P3 success, NDA submission, or FDA approval?
    Any clues as to royalties anticipated?
    Thanks in advance...

  • $$$$
    Please tell me these guys didn't take it this far just to give it away...

  • wilderguide by wilderguide Dec 19, 2014 3:26 PM Flag

    $$$$
    Garo seems to be a "close to the vest" player....undisclosed partnered studies, unknown royalty structures, and under-announced milestone payments. Any chance we're looking at an offering here at $4 anytime soon?
    Rational commentary invited...

  • Reply to

    New high since secondary offering

    by factman777 Dec 26, 2014 11:22 PM
    wilderguide wilderguide Dec 28, 2014 12:37 PM Flag

    $$$$
    See the FDA document dated April 23, 2014 - interesting read:
    "Expedited Access for Premarket Approval Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Diseases or Conditions - Draft Guidance for Industry and Food and Drug Administration"
    To the best of my knowledge, this draft guidance has been issued only for public review and commentary...but is as yet unadopted. My opinion is simply that a balanced measure of expedited access will be struck based upon observed and measurable mechanisms of rehabilitative response and expert perceptions of mitigating unmet patient need in both categories of ASI and CSI.
    GLTA

  • Reply to

    EXEL in 2015

    by duckduffer Dec 31, 2014 2:14 PM
    wilderguide wilderguide Dec 31, 2014 3:01 PM Flag

    $$$$
    Hi duckduffer,
    In addition to your list, I would add that some measure of reporting is also due in 2015 wrt Cabo as it may supplement modulation of the androgen receptor. AR regulation currently remains the most promising targeted therapy in CRPC, and Cabo has shown some promising early responses with Abiraterone...and the PCF is funding further Cabo research with Enzalutamide. No stone will go unturned in determining the significance of splice variant ARv7, and cabozantinib/AR combination research may provide some informative answers.
    Happy New Year!!!

  • wilderguide by wilderguide Jan 2, 2015 4:00 PM Flag

    $$$$
    All today's' trading has really accomplished....
    ...is to validate the contrived illusion of the EXEL market cap for the past couple months...
    Probably see some Form 4 filings come Monday...
    Enjoy your weekend!

  • Reply to

    NVIV: ONLY 9 TRADING DAYS UNTIL PATIENT #1 UPDATE.

    by rwrop Jan 1, 2015 9:19 PM
    wilderguide wilderguide Jan 3, 2015 2:30 PM Flag

    $$$$
    Inasmuch as I would like to see it all, I really don't expect to see much revealed at the 90-day assessment. Detailed trial disclosures are de-prioritized to favor patient privacy, research integrity, and study authorship protection. A short PR suggesting all is well might be expected, but details will await presentation in an appropriate industry venue (ie:ASIA annual meeting) and subsequent peer review prior to publication. One single patient's results will not prove out trial success. Patience...

  • Reply to

    NVIV: ONLY 9 TRADING DAYS UNTIL PATIENT #1 UPDATE.

    by rwrop Jan 1, 2015 9:19 PM
    wilderguide wilderguide Jan 3, 2015 3:41 PM Flag

    $$$$
    "A news story with nationwide exposure..."
    Agreed, but separating science from sensationalism will prove out the potential clinical impact of the NSS. A clinically meaningful 90-day outcome for Jordan may boost short-term share price, but the science will remain unsatisfied pending peer review and responsible presentation of results. Satisfying the statisticians is always the endgame in the clinical trial process.

  • Reply to

    EXEL in 2015

    by duckduffer Dec 31, 2014 2:14 PM
    wilderguide wilderguide Jan 4, 2015 1:14 PM Flag

    $$$$
    One more thought to add here, as I don't see that it has as yet been addressed. The EMA adaptive pathways pilot study is coming of maturity, and if think we'll see that the program come online by 2Q 2015. To date, a handful of drugs have been accepted into this evidence-based licensing program - all YTB made public.
    Cabozantinib's utility in RET-driven disease, DTC, NSCLC, LADC, and in combo with currently approved treatments could easily be said to qualify the drug for such licensing...and might actually inspire some off-label revenues as such imbursements become available. A partial list of EMA-accepted drugs was recently made available to the FDA, and might actually account for last weeks' spike in SP. Time'll tell...

  • Reply to

    what do you think of this article?

    by retsoz Jan 4, 2015 7:29 PM
    wilderguide wilderguide Jan 4, 2015 8:31 PM Flag

    $$$$
    "What do you think...?"
    Amateurish and misleading...full of errors...a bull-pull at best...
    Are you the author?

  • Reply to

    Without news...

    by wilderguide Jan 2, 2015 4:00 PM
    wilderguide wilderguide Jan 5, 2015 10:10 PM Flag

    $$$$
    Thanks for the CPR, hairynutz...
    Without the occasional nitwit showing up Confrontational, Presumptuous, and Rude - it can be downright difficult to differentiate between brain death and the current EXEL YMB.
    Thanks for all your valued contributions, too.
    Dunno where we'd all be w/o you. Truly.
    We're blessed to have you on board.
    Thanks for all that voodoo that only you do.
    Really.

  • Reply to

    when phase 1 will start?

    by ketanmpatel12 Jan 2, 2015 11:34 AM
    wilderguide wilderguide Jan 6, 2015 3:39 AM Flag

    $$$$
    This current 2014 title from the ASCO library may hold some answers for you. "Building on Prostate Cancer Working Group 2 to Change the Paradigm from Palliation to Cure" by HI Scher. Designing a clinically relevant trial in PCa with a high probability of success has become increasingly difficult. Selecting the appropriate patient group can be tricky, and every aspect of the evolving treatment landscape must be considered, lest your treatment be determined obsolete before your P2 data is even mature. Hopefully, Doc Scher remains on board here, and we see a first patient dosed by the end of Q2 2015.

  • $$$$
    Love them like your own children. If they're still here, it's because they are longs in drag.
    They had their chance to cover. If they didn't, they surely missed the boat...
    GS has covered their short, and we'll verify that at the next institutional update.
    My predictions for 2015:
    Hairynutz will marry JonesDexter in a transgender ceremony in Rome, personally attended by the Pope.
    Hairynutz - in a documentably rare physiologic response - will grow a pair of his very own.
    Nomad Celsius will return to this message board - I assure you he never truly left.
    Seymourjiznu will seek gender reassignment, and be successfully received as a New Wave debutante.
    Offsitehelp will file for cerebral bankruptcy, as he will have achieved zero intellectual equity this past year.
    MMM will shine on with great hair...and might actually be recognized for pulling EXEL outta the fire.
    Cabo will pick up biomarker recognition in RET-driven indications across the board, and will become the low-dose drug of choice in preventing bony mets as it will display synergy with the AR manipulators in PCa & BCa - and also with a PDL-1 techno drug yet to be named.
    Roche will make an offer for Cobimetinib, and it will be declined.
    PeeWee Herman will be appointed to the EXEL BOD because Papa Stelios desperately needs a laugh...
    ...and wilderguide will fade away into biotech YMB purgatory. Such is life...
    Prosperity to all...

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.